Bachem Holding Ag Class B · SIX:BANB
Bachem Holding Ag Class B — H1 2021 Earnings Presentation
26 slides from Bachem Holding Ag Class B's earnings presentation, Aug 27, 2021
Slide 1: Half-Year Results 2021
BACHEM HALF-YEAR RESULTS 2021 Date | August 27, 2021 Location | Bubendorf Name | Thomas Meier / Alain Schaffter
Slide 2: Housekeeping
HOUSEKEEPING Write to us in the Q&A section anytime. At the end of the presentation we will have time for questions. 2 Half-Year Results 2021
Slide 3: Speakers
SPEAKERS Thomas Meier Alain Schaffter Daniel Grotzky (Moderator) CEO CFO Head Group Communication 3 Half-Year Results 2021
Slide 4: Agenda
AGENDA • Half-Year Results 2021 Thomas Meier • Financial Review H1 2021 Alain Schaffter • Outlook 2021 Thomas Meier • Q&A All 4 Half-Year Results 2021
Slide 5: Half-Year Results 2021
HALF-YEAR RESULTS 2021 Thomas Meier
Slide 6: Strong growth in first half of 2021
STRONG GROWTH IN FIRST HALF OF 2021 • CHF 239.1 million (+ 35.0%) Sales: • Growth across all product categories & geographies EBIT: • CHF 61.9 million (+ 53.9%) • CAPEX investment of CHF >50 million in first half of the year Capacity: • 107 new positions created to a total of 1 636 employees globall
Slide 7: Key figures H1 2021
KEY FIGURES H1 2021 H1 2021 H1 2020 Change CHF Change LC Sales (in CHF million) 239.1 177.1 + 35.0% + 39.5% EBITDA (in CHF million) 75.5 53.0 + 42.5% + 52.4% in relation to sales 31.6% 29.9% EBIT (in CHF million) 61.9 40.3 + 53.9% + 66.6% in relation to sales 25.9% 22.7% Net income (in CHF million)
Slide 8: Outlook 2021: commitment to profitable growth
OUTLOOK 2021: COMMITMENT TO PROFITABLE GROWTH • CHF 500 million in 2021 Sales: • Average annual growth of about 15% over next five years (2022-2026) EBIT: • Growth by percentage ahead of sales • Global investment volume of over CHF 500 million in the next five Capacity: years 8 Half-Year Results 202
Slide 9: Growth in all product categories
GROWTH IN ALL PRODUCT CATEGORIES Change in in million CHF H1 2021 Change in CHF Sales share local currency Research & Specialties 22.6 +48.1% +43.7% 9.4% CMC Development 68.3 +35.1% +30.7% 28.6% Commercial API 148.2 +40.3% +35.8% 62.0% Total sales 239.1 + 39.5% + 35.0% 100.0% Note to analysts: Forme
Slide 10: Geographically balanced
GEOGRAPHICALLY BALANCED Change in in million CHF H1 2021 Change in CHF Sales share local currency Europe/Asia 116.9 + 42.2% + 41.3% 48.9% North America 122.2 + 36.9% + 29.5% 51.1% Total sales 239.1 + 39.5% + 35.0% 100.0% Stronger balance between Europe/Asia and North America region. North America gr
Slide 11: Update oligonucleotides
UPDATE OLIGONUCLEOTIDES • Oligonucleotide business is on track. • Develop as a second strategic pillar alongside peptides. • Goals remain CHF 100 million sales medium-term, aim to be among top three oligo CDMO. • Expanding commercial activities. • New manufacturing capacity to go online by end of Q4
Slide 12: Sustainability at Bachem: as an element of ongoing business
SUSTAINABILITY AT BACHEM: AS AN ELEMENT OF ONGOING BUSINESS… Bachem’s business model makes ongoing contribution to key UN SDGs Enable treatment of wide Vocational training and Responsible employer and Employee and community range of diseases in ongoing education to strong commitment to safety, sound
Slide 13: Sustainability at Bachem: furthered through specific targets
DEEP-DIVE WEBINAR AUGUST 31, 17:30 CET SUSTAINABILITY AT BACHEM: …AND FURTHERED THROUGH SPECIFIC TARGETS. Energy Consumption Global Greenhouse Gas Emissions • Reduce in energy consumption per FTE • Halve GHG emissions per FTE by 2026 by 20% by 2026 • Achieve climate neutrality by 2030 Diversity and
Slide 14: Financial Review H1 2021
FINANCIAL REVIEW H1 2021 Alain Schaffter
Slide 15: Key figures H1 2021
KEY FIGURES H1 2021 H1 2021 H1 2020 Change CHF Change LC Sales (in CHF million) 239.1 177.1 + 35.0% + 39.5% EBITDA (in CHF million) 75.5 53.0 + 42.5% + 52.4% in relation to sales 31.6% 29.9% EBIT (in CHF million) 61.9 40.3 + 53.9% + 66.6% in relation to sales 25.9% 22.7% Net income (in CHF million)
Slide 16: Drivers of EBIT margin increase from 22.7% to 25.9%
DRIVERS OF EBIT MARGIN INCREASE FROM 22.7% TO 25.9% (IN %) +320bps 0.6 25.9 0.8 0.0 1.8 22.7 EBIT H1 2020 COGS M&S R&D G&A /other income EBIT H1 2021 16 Half-Year Results 2021
Slide 17: Increased operating cash flow by 1.8% to CHF 59.8 million
INCREASED OPERATING CASH FLOW BY 1.8% TO CHF 59.8 MILLION (IN CHF MILLION) 1.8% -8.9 59.8 68.7 58.7 1.8 -16.7 59.8 6.0 -54.6 -9.0 0.3 Operating Cash Operating Cash Flow H1 2020 Flow H1 2021 -3.5 Operating Change in Change in Change in Operating Investing Financing Currency Net change CF before recei
Slide 18: Stable equity ratio
STABLE EQUITY RATIO (IN CHF MILLION) 145.0 710.9 769.0 107.3 60.0 25.0 235.2 281.2 (33%) (37%) 22.3 475.7 487.8 (67%) (63%) 85.0 60.0 Liabilities Equity Dec. 31, 2020 June 30, 2021 Dec. 31, 2020 June 30, 2021 Current loan Ingro Finanz AG Current loans bank Non-current loans bank 18 Half-Year Results
Slide 19: CAPEX overview 2017 – H1 2021
CAPEX OVERVIEW 2017 – H1 2021 76.4 50.4 50.6 38.6 32.7 24.9 25.9 23.1 20.9 21.2 19.3 13.5 19.0 13.7 10.4 2017 2018 2019 2020 H1 2021 CAPEX in CHF million Depreciation in CHF million CAPEX in % of sales 19 Half-Year Results 2021
Slide 20: Outlook 2021
OUTLOOK 2021 Thomas Meier BACHEM
Slide 21: Dynamics & growth drivers
Internal factors • NCE pipeline with >150 projects • US-FDA approved four products with Bachem drug substances in H1 2021 • Strong productivity & profitability dynamic • Success of oligonucleotide offering at all clinical stages DYNAMICS & • Positive results in securing captive peptide business GROW
Slide 22: Outlook 2021: commitment to profitable growth
OUTLOOK 2021: COMMITMENT TO PROFITABLE GROWTH • CHF 500 million in 2021 Sales: • Average annual growth of about 15% over next five years (2022-2026) EBIT: • Growth by percentage ahead of sales • Global investment volume of over CHF 500 million in the next five Capacity: years 22 Half-Year Results 20
Slide 23: Questions
QUESTIONS Write your questions in the Q&A section
Slide 24: Thank you for your attendance!
THANK YOU FOR YOUR ATTENDANCE! Question? Send an e-mail to… ir@bachem.com media@bachem.com 24 Half-Year Results 2021
Slide 25: Disclaimer
DISCLAIMER This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Slide 26: Leading partner
LEADING PARTNER BACHEM ~ 4